Last reviewed · How we verify
Bevacizumab-awwb
Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.
Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | Bevacizumab-awwb |
|---|---|
| Also known as | MVASI |
| Sponsor | Amgen |
| Drug class | VEGF inhibitor monoclonal antibody / Bevacizumab biosimilar |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This drug blocks VEGF, a key signaling molecule that promotes the formation of new blood vessels that tumors need to grow and spread. By preventing VEGF from binding to its receptors on endothelial cells, bevacizumab-awwb starves tumors of their blood supply, slowing or stopping tumor growth. Bevacizumab-awwb is a biosimilar to the reference bevacizumab product, manufactured by Amgen.
Approved indications
- Metastatic colorectal cancer
- Non-squamous non-small cell lung cancer
- Metastatic breast cancer
- Recurrent glioblastoma
- Metastatic renal cell carcinoma
- Persistent, recurrent, or metastatic cervical cancer
Common side effects
- Hypertension
- Proteinuria
- Hemorrhage
- Thromboembolism
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
- Diarrhea
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab-awwb CI brief — competitive landscape report
- Bevacizumab-awwb updates RSS · CI watch RSS
- Amgen portfolio CI